Skip to main content
You have permission to edit this article.
Edit
McLeod Health, HHS expand access to monoclonal antibody therapy to COVID-19 patients in northeast SC
0 Comments

McLeod Health, HHS expand access to monoclonal antibody therapy to COVID-19 patients in northeast SC

  • 0
{{featured_button_text}}

FLORENCE, S.C. − McLeod Health, in partnership with the South Carolina Department of Health and Environmental Control and the U.S. Department of Health and Human Services, has expanded access to COVID-19 monoclonal antibody treatment at multiple locations.

For people who are at high risk for developing severe COVID-19 illness and have tested positive for the COVID-19 virus, this monoclonal antibody treatment (mAb) has been shown to help prevent progression of the disease that might otherwise require hospitalization.

With the rapid spread of the delta variant and only 45% of the population fully vaccinated for the coronavirus, South Carolina is in the midst of a major surge in COVID-19 cases. As of Aug. 9, the state was averaging more than 2,500 cases per day over the past week, up from roughly 200 cases per day a month ago.

In response to the growing need for medical care in the region, McLeod Health is offering expanded access to the mAb infusion for eligible patients at four locations: McLeod Regional Medical Center, McLeod Health Clarendon, McLeod Health Seacoast and McLeod Health Loris.

To confirm eligibility for the treatment, receive a referral and book an appointment, patients should visit McLeodCovid.org or contact the McLeod Health COVID Call Center at 843-777-2919 for more information. A copy of the patient’s positive test result is required to schedule an appointment.

If administered within 10 days of onset of COVID-19 symptoms, the one-time therapy is highly effective in neutralizing the virus and preventing symptoms from worsening. The treatment is administered through intravenous infusion.

“We are pleased to be a part of this important initiative and are committed to ensuring that the most vulnerable individuals in our community have access to COVID-19 care,” said Dr. Dale Lusk, the corporate chief medical officer and senior vice president of quality and safety for McLeod Health.

“Monoclonal antibody treatments have been offered to COVID-19 positive patients at McLeod Health since November of 2020 and continuing to provide this service ensures that we play a pivotal role in helping our region and state recover from this pandemic.

“We know that this treatment can save numerous lives. With the Delta variant again increasing numbers across our state, it is a vital tool to help our patients recover and also curb further spread of COVID-19.”

On March 17, HHS announced it was investing $150 million to increase access to mAb therapy for high-risk patients in underserved and disadvantaged communities across the country. With support from KPMG LLP, HHS is developing new prototype models for expanding access to mAb treatment and leveraging an existing network of health care partners to provide the therapy for underserved and disadvantaged populations.

“South Carolina is seeing a surge in the number of COVID-19 cases that is impossible to ignore, and the delta variant is driving it,” said Dr. Brannon Traxler, the public health director at the South Carolina Department of Health and Environmental Control. “Until we defeat COVID-19, there will continue to be more and more people who find themselves infected, which is why it is so vitally important to have monoclonal antibody therapy treatments available and partners like McLeod Health invested in serving families in underserved areas of South Carolina.”

McLeod is the first provider organization in South Carolina to join this health equity initiative and joins a growing list of mAbs therapy providers supported by KPMG and sponsored by HHS as part of the federal effort to help end COVID-19 and improve health equity in underserved communities across the country.

The therapy is the first COVID-19 treatment granted emergency use authorization by the U.S. Food and Drug Administration for outpatient use. A Phase 3 clinical trial showed that the antibody therapy reduced the risk of hospitalization or death by up to 70% in patients who received the drug intravenously compared to those who received a placebo.

To be eligible for mAb treatment, patients must meet the Emergency Use Authorization (EUA) definition of “high risk.” Same-day COVID-19 tests can be performed, followed by a telemedicine visit for evaluation and qualification for therapy. Following completion of the infusion treatment, patients are monitored onsite for an hour. Treatment is offered regardless of immigration status, health insurance coverage or ability to pay.

0 Comments

Be the first to know

* I understand and agree that registration on or use of this site constitutes agreement to its user agreement and privacy policy.

Related to this story

Most Popular

PAMPLICO, S.C. – The gymnasium of Hannah-Pamplico Elementary-Middle School was filled with cheering students Wednesday afternoon. But the students weren’t cheering for a basketball or volleyball team. Instead, the students were cheering as Assistant Principal Amy McAllister was named the 2022 South Carolina Middle Level Assistant Principal of the Year.

Get up-to-the-minute news sent straight to your device.

Topics

Breaking News

News Alert